Latest Wearable Devices News

Bio-Gene Technology Limited reports strong progress in advancing its Flavocide® and Qcide® insecticidal platforms, backed by US Department of Defense funding and key organic certification in the US.

InteliCare Holdings has advanced its aged care technology deployments and is close to appointing a new CEO, signalling a pivotal growth phase. The company also reported progress in commercial talks and product enhancements.

Control Bionics has partnered with Tobii Dynavox to pilot its NeuroNode technology across five US states, aiming to enhance communication access for users of augmentative devices.

Bio-Gene Technology reports promising progress on its US Department of Defense-funded insecticide projects, with early mosquito mortality evidence from its Flavocide wearable device and pending launch of its Qcide indoor spray program.

Nanoveu’s subsidiary EMASS has completed the design phase of its cutting-edge 16nm ECS-DoT Edge AI system-on-chip, moving closer to fabrication and silicon validation that could redefine ultra-low-power AI at the edge.

Control Bionics has secured $3.25 million through a discounted share placement, aiming to boost its assistive and neurotechnology product growth globally.

Spacetalk Ltd reveals a successful pivot to a software-led, hardware-enabled model, reporting 12% revenue growth and expanding into 15 international markets. The company targets $20–25 million in recurring revenue for 2026, underpinned by new product launches and strategic telco partnerships.

dorsaVi Limited has acquired a cutting-edge neuromorphic processing-in-memory technology portfolio, positioning itself at the forefront of next-generation wearable and robotics intelligence. This strategic move, coupled with leadership changes, signals a new era for the company’s adaptive biosensor and robotics platforms.

Control Bionics has integrated Apple’s Brain-Computer Interface protocol into its NeuroNode products, promising simpler setup and enhanced communication for users with severe impairments.

dorsaVi has launched an evaluation program to scale its oxide-based RRAM technology from 40 nm to 22 nm, aiming for significant gains in density, speed, and energy efficiency. This move could enhance its wearable sensor devices and embedded AI applications.

Control Bionics has successfully raised $0.6 million through a shortfall placement, reinforcing investor confidence as it accelerates commercialisation of its neurotechnology in assistive communication and emerging sports markets.

dorsaVi has achieved a major engineering milestone by validating its RRAM-powered Reflex Platform, delivering neural reflex decisions in under one microsecond with ultra-low energy consumption. This breakthrough paves the way for next-generation robotics, prosthetics, and wearable devices that require rapid, energy-efficient reflex actions.